Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 329 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Body CT Scan Clear all

Conditions: Prostate Cancer
Interventions: SPECT CT, 18F-DCFPyL PET/CT, 18F-NaF PET/CT, WB-MRI; Procedure · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Multiple Myeloma
Interventions: 89Zr-daratumumab, PET/CT scans, Blood draws; Drug · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Opioid Use Disorder
Interventions: Carfentanil, C-11, Naloxone, Loperamide Hydrochloride; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Positron Emission Tomography-Magnetic Resonance (PET-MR)
Interventions: Positron Emission Test / Magnetic Resonance (PET/MR), Positron Emission Test / Computed Tomography (PET/CT); Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Solid Tumor
Interventions: Proton SBRT; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Computed Tomography, Diagnostic Imaging
Interventions: Iopromide 370 mg I/mL, Iopromide 300 mg I/mL; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 17
States / cities: Tucson, Arizona • Miami, Florida • Tallahassee, Florida + 11 more

Conditions: Solid Tumor, Solid Carcinoma, Castration-Resistant Prostate Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Glioma, Malignant
Interventions: 18F-TRX, Positron Emission Tomography (PET)/Computerized tomography (CT), Tumor Biopsy, Blood Specimen Collection; Drug · Procedure
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bone Metastases, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: magnetic resonance imaging, fluorine F 18 sodium fluoride, positron emission tomography, computed tomography, technetium Tc 99m methylene diphosphonate, laboratory biomarker analysis; Procedure · Radiation · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Mild Autonomous Cortisol Secretion (MACS)
Interventions: Various labs and imaging tests; Diagnostic Test
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer, Left Sided Breast Cancer
Interventions: Continuous Positive Airway Pressure, Deep inspiratory breath hold, Free Breath; Device · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Multiple Myeloma
Interventions: 64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT; Drug · Device · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Atrial Fibrillation
Interventions: 3D C-arm CT scan; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sarcoma
Interventions: pegfilgrastim, doxorubicin hydrochloride, ifosfamide, pegylated liposomal doxorubicin hydrochloride, conventional surgery, fludeoxyglucose F 18; Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 16 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 2
States / cities: Baltimore, Maryland • Minneapolis, Minnesota

Conditions: Head and Neck Cancer
Interventions: 64Cu-DOTA-ECL1i; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Tongue Tumor, Tongue Cancer
Interventions: CT Scan, Experimental Oral Stent Device; Diagnostic Test · Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 347
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more

Conditions: Unspecified Adult Solid Tumor
Interventions: stereotactic radiation therapy, implanted fiducial-based imaging, cone-beam computed tomography; Radiation · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Non-Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Renal Cell Carcinoma
Interventions: Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy; Procedure · Other · Radiation
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Duarte, California • Irvine, California

Conditions: Cancer of Kidney, Kidney Cancer, Renal Cancer, Neoplasms, Kidney, Renal Neoplasms, Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma
Interventions: 124-Iodine-cG250 (124I-cG250); Drug
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
Interventions: Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18, Gadolinium, Magnetic Resonance Imaging, Positron Emission Tomography, Three-Dimensional Spoiled Gradient MRI; Procedure · Radiation · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Neoplasm, Lymphoma, Melanoma, Fluorodeoxyglucose, Positron-emission Tomography
Interventions: uEXPLORER/mCT, mCT/uEXPLORER; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Prostate Cancer
Interventions: Medical Device Usage and Evaluation, CT simulation, Stereotactic body radiation therapy, Brachytherapy, Post-implant dosimetry scan; Device · Procedure · Radiation
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Sarcopenia, Body Composition, Obesity
Interventions: Soma Body-Composition Segmentation Software; Diagnostic Test
Lead sponsor: Nucleo Research, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer Disease
Interventions: Challenge A - low calorie Ensure®, Challenge B - Ensure® plus ketone esters (KE), PET Scan, Cognitive Testing - FCSRT, Story Recall, BVRT, CogState One Card Learning; Dietary Supplement · Procedure · Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Search by objective public record fields.

Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody

Multi-System Analysis of Opioid Receptor Binding

Enhancing SUV Accuracy of PET/MR for Clinical Trial Qualification

Online Proton Adaptive Radiotherapy

Ultravist: Safety and Efficacy in Computed Tomography of Head and Body

Imaging of Solid Tumors Using 18F-TRX

Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer

Detecting Mild Autonomous Cortisol Secretion in Patients With Adrenal Incidentaloma

A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose

64Cu-LLP2A for Imaging Multiple Myeloma

Siemens 3-D C-Arm CT of the Heart Chambers

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

Imaging CCR2 Receptors With 64Cu-DOTA-ECL1i in Head and Neck Cancer

Oral Stent Device for Radiation Treatments of Oral Cancers

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Stereotactic Radiation Therapy in Treating Patients With Liver Metastases

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma

Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer

Validation of a Body-Composition Segmentation Software on a Diverse Public CT Scan Cohort

The Brain Ketone Body Challenge Imaging Study